Venaxis Inc. (APPY) 3.52 $APPY
Venaxis Announces Termination of Proposed Transactions with Strand Life Sciences
PR Newswire - Mon Mar 14, 4:00PM CDT
Venaxis®, Inc. (Nasdaq: APPY), announced today that Venaxis, Strand Life Sciences Private Limited (Strand LS) and its U.S. subsidiary Strand Genomics Inc. (SGI), have agreed to terminate the previously announced transactions between the companies. On March 11, 2016, Venaxis, Strand LS and SGI entered into a Mutual Termination Agreement to terminate in full the Master Agreement between them. The termination of the Master Agreement automatically caused a termination of the Asset Purchase Agreement between Venaxis and SGI, and each of the Share Sale Agreements and Investment Agreements between Venaxis and the Strand LS shareholders.
APPY: 3.52 (-0.09)
Venaxis Announces Transaction with Strand Life Sciences
PR Newswire - Tue Jan 26, 3:10PM CST
Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders. Strand LS is a privately-held, global genomics and bioinformatics company. Strand LS operates clinical reference labs in the US through its wholly owned subsidiary Strand Genomics, Inc., (Strand U.S.) and directly in India, providing testing and lab services in India and other world-wide markets. Strand LS has commercialized a next generation sequencing (NGS) based, targeted, multi-gene, pan-cancer diagnostic panel in select international markets and has engaged in initial commercialization activities in the United States.
APPY: 3.52 (-0.09)
Global Diagnostics Partnering 2010-2015: Deal Trends, Players, Financials and Forecasts for 150+ Companies
M2 - Tue Sep 22, 6:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hm3w3j/global) has announced the addition of the "Global Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering. The Global Diagnostics Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: - Companion Diagnostics - Imaging - CT - Endoscope - Molecular and nuclear - MRI - Ultrasound - X-ray - PET - SPECT - Angiography - Fluroscopy - Mammography - In vitro diagnostics - Molecular diagnostics - Prognostics - Theranostics Report scope: Global Diagnostics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide. Global Diagnostics Partnering 2010-2015 includes: - Trends in diagnostic dealmaking in the biopharma industry since 2010 - Analysis of diagnostic deal structure - Case studies of real-life diagnostic deals - Access to over 3,000 diagnostic deals - The leading diagnostic deals by value since 2010 - Most active diagnostic dealmakers since 2010 - The leading diagnostic partnering resources In Global Diagnostics Partnering 2010-2015 , the available contracts are listed by: - Headline value - Stage of development at signing - Deal component type - Specific therapy target Companies Mentioned - Partial List - Abaxis - Abbott Laboratories - Accuray - Achaogen - Actavis (acquired by Watson) - Acusphere - ADMA Biologics - Aegea Biotechnologies - Alnylam Pharmaceuticals - Alseres Pharmaceuticals - Altair Nanotechnologies - Amarantus BioSciences - Ambit Biosciences - AMDL Diagnostics - AmpliPhi Biosciences - Amway Global - ARK Diagnostics - Arno Therapeutics - Arrayit - Arrayit Diagnostics - AspenBio Pharma - Asuragen - Atossa Genetics - Audeo Oncology - Axial Biotech - Bayer Schering Pharma - Beckman Coulter - Beijing C&D - BG Medicine - Bio-Imaging Technologies - Bio-Matrix Scientific - Biocept - BioClinica - Biofield - Biogen Idec For more information visit http://www.researchandmarkets.com/research/hm3w3j/global
BIIB: 234.60 (+1.60), ABT: 38.74 (+1.01), ADMA: 7.06 (+0.06), APPY: 3.52 (-0.09), APHB: 1.71 (unch), ATOS: 0.32 (-0.01), ABAX: 45.30 (-0.68)
Hot Stock: AspenBio Pharma, Shares Drop 5.1% (APPY)
Comtex SmarTrend(R) - Mon Jun 08, 10:44AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing penny stocks, down 5.1% to $0.56 on 1.1x average daily volume. AspenBio Pharma has traded 377,000 shares thus far today, vs. average volume of 336,000 shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.2%) and underperformed the S&P 500 (-5.1% to the S&P's -0.3%) during today's trading.
APPY: 3.52 (-0.09)
Stock to Watch: AspenBio Pharma Up 5.4% (APPY)
Comtex SmarTrend(R) - Fri Jun 05, 10:17AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 5.4% to $0.59 on 3.1x average daily volume. AspenBio Pharma has traded 2.3 million shares thus far today, vs. average volume of 719,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.1%) and outperformed the S&P 500 (5.4% to the S&P's -0.1%) during today's trading.
APPY: 3.52 (-0.09)
Hot Stock: AspenBio Pharma, Shares Gain 11.5% (APPY)
Comtex SmarTrend(R) - Tue Apr 21, 10:17AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 11.5% to $0.60 on 8.7x average daily volume. AspenBio Pharma has traded 3.8 million shares thus far today, vs. average volume of 441,000 shares per day. The stock has outperformed the Dow (11.5% to the Dow's -0.2%) and outperformed the S&P 500 (11.5% to the S&P's 0.1%) during today's trading.
APPY: 3.52 (-0.09)
AspenBio Pharma Up 8.7%, Penny Stock Attracts Attention (APPY)
Comtex SmarTrend(R) - Tue Apr 14, 10:46AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 8.7% to $0.52 on 2.1x average daily volume. Thus far today, AspenBio Pharma has traded 1.3 million shares, vs. average volume of 613,000 shares per day. The stock has outperformed the Dow (8.7% to the Dow's 0.1%) and outperformed the S&P 500 (8.7% to the S&P's -0.1%) during today's trading.
APPY: 3.52 (-0.09)
Stock to Watch: AspenBio Pharma Up 11.5% (APPY)
Comtex SmarTrend(R) - Fri Apr 10, 11:45AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 11.5% to $0.50 on 1.2x average daily volume. Thus far today, AspenBio Pharma has traded 742,000 shares, vs. average volume of 606,000 shares per day. The stock has outperformed the Dow (11.5% to the Dow's 0.4%) and outperformed the S&P 500 (11.5% to the S&P's 0.5%) during today's trading.
APPY: 3.52 (-0.09)
Venaxis to Provide Business Update
PR Newswire - Mon Apr 06, 8:00AM CDT
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced that the Company will host an investor conference call to discuss FDA updates, European commercial activities, product development and other corporate matters. The April 7, 2015, 4:30 p.m. ET, conference call will be hosted by Steve Lundy, President and CEO.
APPY: 3.52 (-0.09)
Traders Get Bullish on Shares of AspenBio Pharma, Shares Up 6.2% (APPY)
Comtex SmarTrend(R) - Thu Apr 02, 11:45AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 6.2% to $0.49 on 1.0x average daily volume. AspenBio Pharma has traded 692,000 shares thus far today, vs. average volume of 675,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.2%) and outperformed the S&P 500 (6.2% to the S&P's 0.3%) during today's trading.
APPY: 3.52 (-0.09)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Venaxis, Inc. and a Lead Plaintiff Deadline of April 3, 2015 -- APPY
GlobeNewswire - Tue Mar 24, 4:19PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq:APPY) securities between March 13, 2014 and January 28, 2015.
APPY: 3.52 (-0.09)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Venaxis, Inc. of Class Action Lawsuit and Upcoming Deadline -- APPY
GlobeNewswire - Fri Mar 20, 2:51PM CDT
Pomerantz LLP has filed a class action lawsuit against Venaxis, Inc. ("Venaxis" or the "Company" (Nasdaq:APPY) and certain of its officers. The class action, filed in United States District Court, The District of Colorado, and docketed under 15-cv-00222, is on behalf of a class consisting of all persons or entities who purchased Venaxis securities between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
APPY: 3.52 (-0.09)
APPY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Venaxis, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of April 3, 2015 -- APPY
GlobeNewswire - Fri Mar 20, 8:00AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company" (Nasdaq:APPY) securities between March 13, 2014 and January 28, 2015.
APPY: 3.52 (-0.09)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Venaxis, Inc.
BusinessWire - Thu Mar 19, 4:32PM CDT
Law Offices of Howard G. Smith reminds investors that purchasers of the securities of Venaxis, Inc. ("Venaxis" or the "Company" (NASDAQ:APPY) between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" , have until April 3, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of Colorado.
APPY: 3.52 (-0.09)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Venaxis, Inc.
BusinessWire - Fri Mar 13, 11:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Venaxis, Inc. ("Venaxis" or the "Company" (NASDAQ:APPY) that purchasers of Venaxis securities between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" , have until April 3, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of Colorado.
APPY: 3.52 (-0.09)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Venaxis, Inc. and a Lead Plaintiff Deadline of April 3, 2015 -- APPY
GlobeNewswire - Tue Mar 10, 4:21PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company" (Nasdaq:APPY) securities between March 13, 2014 and January 28, 2015.
APPY: 3.52 (-0.09)
VENAXIS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Venaxis, Inc. To Contact The Firm - APPY
PR Newswire - Mon Mar 09, 3:45PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Venaxis, Inc. ("Venaxis" or the "Company" (NASDAQ: APPY) of the April 3, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Venaxis and certain officers of the Company.
APPY: 3.52 (-0.09)
Venaxis Announces Termination of Proposed Transactions with Strand Life Sciences
PR Newswire - Mon Mar 14, 4:00PM CDT
Venaxis®, Inc. (Nasdaq: APPY), announced today that Venaxis, Strand Life Sciences Private Limited (Strand LS) and its U.S. subsidiary Strand Genomics Inc. (SGI), have agreed to terminate the previously announced transactions between the companies. On March 11, 2016, Venaxis, Strand LS and SGI entered into a Mutual Termination Agreement to terminate in full the Master Agreement between them. The termination of the Master Agreement automatically caused a termination of the Asset Purchase Agreement between Venaxis and SGI, and each of the Share Sale Agreements and Investment Agreements between Venaxis and the Strand LS shareholders.
APPY: 3.52 (-0.09)
Venaxis Announces Transaction with Strand Life Sciences
PR Newswire - Tue Jan 26, 3:10PM CST
Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders. Strand LS is a privately-held, global genomics and bioinformatics company. Strand LS operates clinical reference labs in the US through its wholly owned subsidiary Strand Genomics, Inc., (Strand U.S.) and directly in India, providing testing and lab services in India and other world-wide markets. Strand LS has commercialized a next generation sequencing (NGS) based, targeted, multi-gene, pan-cancer diagnostic panel in select international markets and has engaged in initial commercialization activities in the United States.
APPY: 3.52 (-0.09)
Global Diagnostics Partnering 2010-2015: Deal Trends, Players, Financials and Forecasts for 150+ Companies
M2 - Tue Sep 22, 6:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hm3w3j/global) has announced the addition of the "Global Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering. The Global Diagnostics Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: - Companion Diagnostics - Imaging - CT - Endoscope - Molecular and nuclear - MRI - Ultrasound - X-ray - PET - SPECT - Angiography - Fluroscopy - Mammography - In vitro diagnostics - Molecular diagnostics - Prognostics - Theranostics Report scope: Global Diagnostics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide. Global Diagnostics Partnering 2010-2015 includes: - Trends in diagnostic dealmaking in the biopharma industry since 2010 - Analysis of diagnostic deal structure - Case studies of real-life diagnostic deals - Access to over 3,000 diagnostic deals - The leading diagnostic deals by value since 2010 - Most active diagnostic dealmakers since 2010 - The leading diagnostic partnering resources In Global Diagnostics Partnering 2010-2015 , the available contracts are listed by: - Headline value - Stage of development at signing - Deal component type - Specific therapy target Companies Mentioned - Partial List - Abaxis - Abbott Laboratories - Accuray - Achaogen - Actavis (acquired by Watson) - Acusphere - ADMA Biologics - Aegea Biotechnologies - Alnylam Pharmaceuticals - Alseres Pharmaceuticals - Altair Nanotechnologies - Amarantus BioSciences - Ambit Biosciences - AMDL Diagnostics - AmpliPhi Biosciences - Amway Global - ARK Diagnostics - Arno Therapeutics - Arrayit - Arrayit Diagnostics - AspenBio Pharma - Asuragen - Atossa Genetics - Audeo Oncology - Axial Biotech - Bayer Schering Pharma - Beckman Coulter - Beijing C&D - BG Medicine - Bio-Imaging Technologies - Bio-Matrix Scientific - Biocept - BioClinica - Biofield - Biogen Idec For more information visit http://www.researchandmarkets.com/research/hm3w3j/global
BIIB: 234.60 (+1.60), ABT: 38.74 (+1.01), ADMA: 7.06 (+0.06), APPY: 3.52 (-0.09), APHB: 1.71 (unch), ATOS: 0.32 (-0.01), ABAX: 45.30 (-0.68)
Hot Stock: AspenBio Pharma, Shares Drop 5.1% (APPY)
Comtex SmarTrend(R) - Mon Jun 08, 10:44AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing penny stocks, down 5.1% to $0.56 on 1.1x average daily volume. AspenBio Pharma has traded 377,000 shares thus far today, vs. average volume of 336,000 shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.2%) and underperformed the S&P 500 (-5.1% to the S&P's -0.3%) during today's trading.
APPY: 3.52 (-0.09)
Stock to Watch: AspenBio Pharma Up 5.4% (APPY)
Comtex SmarTrend(R) - Fri Jun 05, 10:17AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 5.4% to $0.59 on 3.1x average daily volume. AspenBio Pharma has traded 2.3 million shares thus far today, vs. average volume of 719,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.1%) and outperformed the S&P 500 (5.4% to the S&P's -0.1%) during today's trading.
APPY: 3.52 (-0.09)
Hot Stock: AspenBio Pharma, Shares Gain 11.5% (APPY)
Comtex SmarTrend(R) - Tue Apr 21, 10:17AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 11.5% to $0.60 on 8.7x average daily volume. AspenBio Pharma has traded 3.8 million shares thus far today, vs. average volume of 441,000 shares per day. The stock has outperformed the Dow (11.5% to the Dow's -0.2%) and outperformed the S&P 500 (11.5% to the S&P's 0.1%) during today's trading.
APPY: 3.52 (-0.09)
AspenBio Pharma Up 8.7%, Penny Stock Attracts Attention (APPY)
Comtex SmarTrend(R) - Tue Apr 14, 10:46AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 8.7% to $0.52 on 2.1x average daily volume. Thus far today, AspenBio Pharma has traded 1.3 million shares, vs. average volume of 613,000 shares per day. The stock has outperformed the Dow (8.7% to the Dow's 0.1%) and outperformed the S&P 500 (8.7% to the S&P's -0.1%) during today's trading.
APPY: 3.52 (-0.09)
Stock to Watch: AspenBio Pharma Up 11.5% (APPY)
Comtex SmarTrend(R) - Fri Apr 10, 11:45AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 11.5% to $0.50 on 1.2x average daily volume. Thus far today, AspenBio Pharma has traded 742,000 shares, vs. average volume of 606,000 shares per day. The stock has outperformed the Dow (11.5% to the Dow's 0.4%) and outperformed the S&P 500 (11.5% to the S&P's 0.5%) during today's trading.
APPY: 3.52 (-0.09)
Venaxis to Provide Business Update
PR Newswire - Mon Apr 06, 8:00AM CDT
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced that the Company will host an investor conference call to discuss FDA updates, European commercial activities, product development and other corporate matters. The April 7, 2015, 4:30 p.m. ET, conference call will be hosted by Steve Lundy, President and CEO.
APPY: 3.52 (-0.09)
Traders Get Bullish on Shares of AspenBio Pharma, Shares Up 6.2% (APPY)
Comtex SmarTrend(R) - Thu Apr 02, 11:45AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing penny stocks, up 6.2% to $0.49 on 1.0x average daily volume. AspenBio Pharma has traded 692,000 shares thus far today, vs. average volume of 675,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.2%) and outperformed the S&P 500 (6.2% to the S&P's 0.3%) during today's trading.
APPY: 3.52 (-0.09)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Venaxis, Inc. and a Lead Plaintiff Deadline of April 3, 2015 -- APPY
GlobeNewswire - Tue Mar 24, 4:19PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq:APPY) securities between March 13, 2014 and January 28, 2015. APPY: 3.52 (-0.09)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Venaxis, Inc. of Class Action Lawsuit and Upcoming Deadline -- APPY
GlobeNewswire - Fri Mar 20, 2:51PM CDT
Pomerantz LLP has filed a class action lawsuit against Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq:APPY) and certain of its officers. The class action, filed in United States District Court, The District of Colorado, and docketed under 15-cv-00222, is on behalf of a class consisting of all persons or entities who purchased Venaxis securities between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . APPY: 3.52 (-0.09)
APPY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Venaxis, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of April 3, 2015 -- APPY
GlobeNewswire - Fri Mar 20, 8:00AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq:APPY) securities between March 13, 2014 and January 28, 2015. APPY: 3.52 (-0.09)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Venaxis, Inc.
BusinessWire - Thu Mar 19, 4:32PM CDT
Law Offices of Howard G. Smith reminds investors that purchasers of the securities of Venaxis, Inc. ("Venaxis" or the "Company"
(NASDAQ:APPY) between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" , have until April 3, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of Colorado. APPY: 3.52 (-0.09)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Venaxis, Inc.
BusinessWire - Fri Mar 13, 11:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Venaxis, Inc. ("Venaxis" or the "Company"
(NASDAQ:APPY) that purchasers of Venaxis securities between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" , have until April 3, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of Colorado. APPY: 3.52 (-0.09)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Venaxis, Inc. and a Lead Plaintiff Deadline of April 3, 2015 -- APPY
GlobeNewswire - Tue Mar 10, 4:21PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq:APPY) securities between March 13, 2014 and January 28, 2015. APPY: 3.52 (-0.09)
VENAXIS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Venaxis, Inc. To Contact The Firm - APPY
PR Newswire - Mon Mar 09, 3:45PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Venaxis, Inc. ("Venaxis" or the "Company"
(NASDAQ: APPY) of the April 3, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Venaxis and certain officers of the Company. APPY: 3.52 (-0.09)
